Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Clinical trial shows effectiveness of ponatinib in patients with leukemia and lymphoma

Huntsman Cancer Institute researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma.

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

Boehringer Ingelheim today announced that new data evaluating volasertib, an investigational polo-like kinase (Plk) inhibitor, will be presented at the 54th American Society of Hematology (ASH) annual meeting taking place December 8-11 in Atlanta, Ga.

30 Nov 2012

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.

29 Nov 2012

Interim GALAXY Phase 2b lung cancer study results to be presented at APLCC 2012

Synta Pharmaceuticals Corp. announced today that interim results of the Phase 2b portion of the GALAXY program will be presented on November 28, 2012 at 12:15 p.m. (JST) during the "Highlights of Oral Presentations" session at the Fifth Asia Pacific Lung Cancer Conference (APLCC 2012) in Fukuoka City, Japan.

26 Nov 2012

Adding bortezomib ‘boosts acute myeloid leukemia chemotherapy response’

Older patients with untreated acute myeloid leukemia may benefit from having bortezomib added to daunorubicin and cytarabine during induction therapy and to consolidation intermediate-dose cytarabine, the results of a US study indicate.

14 Nov 2012

Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

Synta Pharmaceuticals Corp. announced today that interim results from the Phase 2b/3 GALAXY trial will be presented at the Chemotherapy Foundation Symposium in New York City on Friday, November 9 during the 11:45 a.m. session on new agents for lung cancer. Presenting this data at the conference will be Dr. Suresh Ramalingham, Professor, Hematology & Medical Oncology, and Director, Translational Thoracic Malignancies Program, of the Winship Cancer Institute of Emory University.

7 Nov 2012

Ion AmpliSeq Community Panels from Life Technologies

Life Technologies Corporation today announced Ion AmpliSeq Community Panels, a community-driven solution to gene panel sequencing that leverages the expertise of scientific thought leaders and the Ion Community to create gene panels for conditions ranging from cancer to inherited diseases.

7 Nov 2012

Sapacitabine tolerated, efficacious in elderly leukemia patients

The nucleoside analog sapacitabine appears to be “active and tolerable” in elderly patients with acute myeloid leukemia, say authors of a phase II study reported in the Lancet Oncology.

5 Nov 2012

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Physician-researchers at Indiana University School of Medicine have reported the first effective therapy for a class of previously untreatable and potentially life-threatening tumors often found in children.

2 Nov 2012

Pins made of single atoms to fight cancer

Answers are often elusive in the fight against cancer, and Rice University chemist Zachary Ball is hoping to pin one down -- with pins made of single atoms. The work, which aims to create a drug that's effective against an "undruggable" protein, is one of the first 50 proposals funded under the National Cancer Institute's (NCI) Provocative Questions Project.

31 Oct 2012

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that it intends to conduct an interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

25 Oct 2012

FDA accepts ARIAD’s ponatinib NDA for filing

ARIAD Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for accelerated review of ARIAD's investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

25 Oct 2012

BioLineRx completes pre-clinical development of BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today that it has successfully completed the pre-clinical development of BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus (HCV), and plans to commence a Phase I/II safety and efficacy study for BL-8020 in Europe during the first quarter of 2013.

17 Oct 2012

Researcher uncovers mechanisms involved in prognosis of acute myeloid leukemia

When patients suffering from Acute Myeloid Leukemia (AML) express high levels of the gene, MN1, an already aggressive leukemia is accelerated and shortens survival time. While that's a known fact, the mechanisms involved aren't well understood which is why a Wake Forest Baptist Medical Center researcher decided to take a closer look.

16 Oct 2012

AAPS recognizes top scientists in pharmaceutical sciences

During the Opening Session of the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, AAPS President David Y. Mitchell, Ph.D., presented the following ground-breaking researchers with awards commemorating their contributions to the pharmaceutical sciences:

15 Oct 2012

Novel method can determine how ready acute myeloid leukemia cells are to die

Researchers at Dana-Farber Cancer Institute have developed a novel method for determining how ready acute myeloid leukemia (AML) cells are to die, a discovery that may help cancer specialists to choose treatments option more effectively for their patients who have AML.

12 Oct 2012

Johns Hopkins joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Johns Hopkins University School of Medicine in Baltimore, MD has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML).

9 Oct 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy.

28 Sep 2012